For the Inventor, By the Inventor

Enter assignee name

Watertown, MA, United States of America

Selecta Biosciences, Inc.

USPTO Granted Patents = 32

EPO Patents = 14

Trademarks = 2

Forward Citations = 639

Loading Chart...

Loading Chart...

15 inventors (with patents filed for the assignee):

Roberto A Maldonado (19 out of 19 patents)

Takashi Kei Kishimoto (14 out of 25 patents)

Christopher C Fraser (11 out of 26 patents)

4. Grayson B Lipford (8 out of 23 patents)

5. Charles M Zepp (6 out of 57 patents)

6. Yun Gao (4 out of 40 patents)

7. Lloyd Johnston (4 out of 16 patents)

8. David H Altreuter (3 out of 9 patents)

9. Petr Ilyinskii (3 out of 3 patents)

10. Fen-ni Fu (3 out of 3 patents)

11. Mark J Keegan (3 out of 3 patents)

12. Sam Baldwin (3 out of 5 patents)

13. Aaron P Griset (2 out of 2 patents)

14. Christopher J Roy (2 out of 2 patents)

15. Conlin O'Neil (1 out of 1 patent)

32 patents: Sort by Forward Citations

1. 11779641 - Tolerogenic synthetic nanocarriers for allergy therapy (2023-10-10),

2. 11717569 - Tolerogenic synthetic nanocarriers (2023-08-08),

3. 11633422 - Methods and compositions for attenuating anti-viral transfer vector immune responses (2023-04-25),

4. 11426451 - Methods and compositions related to combined treatment with antiinflammatories and synthetic nanocarriers comprising an immunosuppressant (2022-08-30),

5. 11298342 - Methods providing a therapeutic macromolecule and synthetic nanocarriers comprising immunosuppressant locally and concomitantly to reduce both type I and type IV hypersensitivity (2022-04-12),

6. 11235057 - Methods for providing polymeric synthetic nanocarriers for generating antigen-specific tolerance immune responses (2022-02-01),

7. 10933129 - Methods for administering synthetic nanocarriers that generate humoral and cytotoxic T lymphocyte responses (2021-03-02),

8. 10668053 - Tolerogenic synthetic nanocarriers to reduce or prevent anaphylaxis in response to a non-allergenic antigen (2020-06-02),

9. 10441651 - Tolerogenic synthetic nanocarriers for generating CD8+ regulatory T cells (2019-10-15),

10. 10434088 - Methods related to administering immunosuppressants and therapeutic macromolecules at a reduced pharmacodynamically effective dose (2019-10-08),

11. 10420835 - Tolerogenic synthetic nanocarriers for antigen-specific deletion of T effector cells (2019-09-24),

12. 10357483 - Methods comprising dosing combinations for reducing undesired humoral immune responses (2019-07-23),

13. 10357482 - Methods providing a therapeutic macromolecule and synthetic nanocarriers comprising immunosuppressant locally and concomitantly to reduce both type I and type IV hypersensitivity (2019-07-23),

14. 10335395 - Methods of administering immunosuppressants having a specified pharmacodynamic effective life and therapeutic macromolecules for the induction of immune tolerance (2019-07-02),

15. 10071114 - Methods and compositions for attenuating gene expression modulating anti-viral transfer vector immune responses (2018-09-11),

Selecta Biosciences, Inc. is a clinical-stage biotechnology company. They develop targeted therapies using their proprietary Synthetic Vaccine Particle (SVP) platform. Selecta's technology enables modulation of the immune system to prevent and treat a range of diseases. Their pipeline includes potential treatments for autoimmune diseases, allergies, and rare diseases. Through their innovative approach, Selecta aims to transform patient care and improve outcomes.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

32 Patents

#12 in Watertown, MA

#606 in Massachusetts

#10,247 in US

#20,095 in the World

Watertown, MA, United States of America

Selecta Biosciences, Inc.

Forward Citations = 639

15 inventors:

Roberto A Maldonado (19 out of 19 patents)

Takashi Kei Kishimoto (14 out of 25 patents)

Christopher C Fraser (11 out of 26 patents)

4. Grayson B Lipford (8 out of 23 patents)

5. Charles M Zepp (6 out of 57 patents)

Please report any incorrect information to support@idiyas.com

Loading…